The Fort Worth Press - Anti-obesity drugs fatten Novo Nordisk profits

USD -
AED 3.672945
AFN 67.732769
ALL 92.653778
AMD 386.383589
ANG 1.793612
AOA 912.499173
ARS 998.537299
AUD 1.53813
AWG 1.7975
AZN 1.696025
BAM 1.846296
BBD 2.009412
BDT 118.926471
BGN 1.848015
BHD 0.376916
BIF 2939.110734
BMD 1
BND 1.337959
BOB 6.877118
BRL 5.784395
BSD 0.995167
BTN 83.976834
BWP 13.577578
BYN 3.256459
BYR 19600
BZD 2.006013
CAD 1.40213
CDF 2869.99994
CHF 0.883602
CLF 0.035257
CLP 972.849973
CNY 7.241015
CNH 7.240975
COP 4397
CRC 506.839358
CUC 1
CUP 26.5
CVE 104.091342
CZK 23.918024
DJF 177.218297
DKK 7.05509
DOP 59.963561
DZD 133.512031
EGP 49.502755
ERN 15
ETB 123.19576
EUR 0.945755
FJD 2.269703
FKP 0.789317
GBP 0.79015
GEL 2.725002
GGP 0.789317
GHS 15.87354
GIP 0.789317
GMD 71.000078
GNF 8576.337427
GTQ 7.688967
GYD 208.211005
HKD 7.78163
HNL 25.139006
HRK 7.133259
HTG 130.736045
HUF 384.322504
IDR 15845.35
ILS 3.732035
IMP 0.789317
INR 84.410599
IQD 1303.760903
IRR 42092.485341
ISK 136.659449
JEP 0.789317
JMD 157.953365
JOD 0.709298
JPY 153.949501
KES 129.249677
KGS 86.493742
KHR 4021.485684
KMF 464.750268
KPW 899.999621
KRW 1394.379834
KWD 0.30744
KYD 0.829306
KZT 496.568521
LAK 21864.232378
LBP 89121.220417
LKR 289.952894
LRD 182.618875
LSL 18.023902
LTL 2.95274
LVL 0.60489
LYD 4.860688
MAD 9.964411
MDL 18.083469
MGA 4652.040932
MKD 58.216651
MMK 3247.960992
MNT 3397.999946
MOP 7.979723
MRU 39.679603
MUR 46.279836
MVR 15.460315
MWK 1725.746004
MXN 20.24817
MYR 4.469499
MZN 63.925032
NAD 18.023902
NGN 1667.789733
NIO 36.627616
NOK 11.02076
NPR 134.362934
NZD 1.699221
OMR 0.385014
PAB 0.995176
PEN 3.78284
PGK 4.003549
PHP 58.809002
PKR 276.467168
PLN 4.091265
PYG 7756.899506
QAR 3.629532
RON 4.706696
RSD 110.63602
RUB 100.505221
RWF 1367.129236
SAR 3.753975
SBD 8.36952
SCR 13.620034
SDG 601.498585
SEK 10.938975
SGD 1.33917
SHP 0.789317
SLE 22.650317
SLL 20969.504736
SOS 568.77183
SRD 35.404965
STD 20697.981008
SVC 8.708417
SYP 2512.529858
SZL 18.017219
THB 34.579605
TJS 10.589063
TMT 3.5
TND 3.145538
TOP 2.342099
TRY 34.603415
TTD 6.756285
TWD 32.394994
TZS 2653.981968
UAH 41.216346
UGX 3654.265512
UYU 42.678725
UZS 12750.752849
VES 45.25428
VND 25400
VUV 118.722009
WST 2.791591
XAF 619.22752
XAG 0.031857
XAU 0.000381
XCD 2.70255
XDR 0.757089
XOF 619.224597
XPF 112.582719
YER 249.850063
ZAR 18.055885
ZMK 9001.202932
ZMW 27.443206
ZWL 321.999592
  • RBGPF

    59.7500

    59.75

    +100%

  • CMSC

    0.0540

    24.624

    +0.22%

  • SCS

    -0.0300

    13.2

    -0.23%

  • CMSD

    -0.0500

    24.39

    -0.21%

  • RELX

    0.5900

    45.04

    +1.31%

  • BCC

    1.4500

    141.54

    +1.02%

  • NGG

    0.1500

    62.9

    +0.24%

  • RIO

    1.1400

    62.12

    +1.84%

  • GSK

    0.3400

    33.69

    +1.01%

  • AZN

    0.1600

    63.39

    +0.25%

  • JRI

    0.1300

    13.23

    +0.98%

  • BCE

    0.4100

    27.23

    +1.51%

  • BTI

    0.2900

    36.68

    +0.79%

  • RYCEF

    0.0800

    6.93

    +1.15%

  • VOD

    0.1500

    8.92

    +1.68%

  • BP

    0.4400

    29.42

    +1.5%

Anti-obesity drugs fatten Novo Nordisk profits
Anti-obesity drugs fatten Novo Nordisk profits / Photo: © AFP/File

Anti-obesity drugs fatten Novo Nordisk profits

Danish drugmaker Novo Nordisk reported Thursday a sharp rise in third quarter sales and profits driven by the success of its anti-diabetes and anti-obesity treatments Ozempic and Wegovy.

Text size:

Net profit rose to 22.5 billion kroner ($3.2 billion) in the period from July to September, a 56 percent increase from the same time last year.

Sales meanwhile rose 29 percent to 58.7 billion kroner.

The results came in slightly better than analyst forecasts of a net profit of around 21.5 billion kroner on sales of 57.7 billion.

Over the first nine months of the year, sales rose by 33 percent to 166.4 billion kroner at constant exchange rates, with a 58 percent jump in sales for Ozempic and a near five-fold increase for Wegovy.

"We are very satisfied with the sales growth in the first nine months of 2023, which is reflecting that more people than ever are benefiting from our innovative diabetes and obesity treatments," chief executive Lars Fruergaard Jorgensen said in a comment.

Ozempic is an injectable anti-diabetic treatment which became wildly popular on social networks for its slimming properties, even though it is not approved for such use.

Novo Nordisk then launched Wegovy, which has the same active ingredient as Ozempic in a different dose, but which was approved by US regulators to treat obesity.

Wegovy is also marketed in Denmark, Norway, the United Kingdom and Germany.

Obesity, which leads to many people developing diabetes, is a growing health problem, with the World Obesity Federation estimating that one in four people could be obese by 2035.

The success of the drugs has led to Novo Nordisk becoming a darling among investors who have driven up the company's share price so much that the company is now Europe's largest by market capitalisation.

Novo Nordisk, which employs nearly 61,400 people in 80 countries, has also become one of the main drivers of the Danish economy.

Over the first six months of the year, GDP of the small Scandinavian country rose by 1.7 percent year-on-year, but without the contribution of the pharmaceutical industry it would have fallen by 0.3 percent, according to the national statistics office.

In its quarterly report, Novo Nordisk maintained its annual outlook of an increase in annual operating profit of between 40 and 46 percent on a rise in sales of between 32 and 38 percent.

J.P.Estrada--TFWP